Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ITGB3 | P05106 | 1/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 1/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | GGT1 | P19440 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.86 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL1331740 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL1353 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL10456693 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL7580 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21722099 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL20484785 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL4303603 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21488922 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL21328429 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 | |
| Aspirin SCHEMBL7762350 | 0.98 | KDM4E (0.96) | KDM4EHSD17B10ALDH1A1HPGDESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1909 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081117-B9 | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | FRESENIUS MEDICAL CARE HOLDINGS INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122027320-A | Intelligent OTA flow identification method based on machine learning | 陕西航星数科信息技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4153561-B1 | 9H-FLUOREN DERIVATES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | UNIV JAGIELLONSKI (PL) | 2026-04-29 | — | — | EP | claimed |
| EP-4732002-A2 | MOLECULAR SIGNATURES OF LONG-TERM HEPATOCELLULAR CARCINOMA RISK IN NON-ALCOHOLIC FATTY LIVER DISEASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4469717-B1 | IMPROVED LIQUID GAS SAMPLE VAPORIZER CONDITIONING SYSTEM AND METHOD | MUSTANG SAMPLING LLC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3269258-B1 | METHOD FOR CROSSLINKING BIOPOLYMERS | NIG NAHRUNGS INGENIEURTECHNIK GMBH (DE) | 2026-03-18 | — | — | EP | claimed |
| CN-121585748-A | Data transmission device and magnetic resonance data acquisition and transmission system | 北京万东医疗科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4680264-A2 | INTERFERON PRODRUGS | Jazz Pharmaceuticals Ireland Limited (IE) | 2026-01-21 | — | — | EP | claimed |
| EP-3717978-B1 | COMPOUNDING DEVICE SYSTEM | OMNICELL INC (US) | 2026-01-14 | — | — | EP | claimed |
| EP-4081117-B1 | CONNECTED DRUG DELIVERY SYSTEM FOR ERYTHROPOIETIN STIMULATING AGENTS | FRESENIUS MEDICAL CARE HOLDINGS INC (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2022119840-A1 | METHODS AND COMPOSITIONS FOR CANNABINOID-BASED THERAPEUTICS | OJAI ENERGETICS PBC (US) | 2022-06-09 | — | — | WO | claimed |
| EP-4003058-A1 | NATURAL VANILLIN COMPOSITIONS | RHODIA OPERATIONS (FR) | 2022-06-01 | — | — | EP | claimed |
| CN-114281945-A | Carbon reduction strategy knowledge base construction method based on green product case base | 合肥工业大学 | 2022-04-05 | — | — | CN | claimed |
| US-11285174-B2 | Macrophage-based therapy for use in the treatment of liver injury | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2022-03-29 | — | — | US | claimed |
| EP-3964838-A2 | CALIBRATION CURVE SETTING METHOD, SPECIMEN ANALYSIS METHOD, CALIBRATION CURVE SETTING PROGRAM, SPECIMEN ANALYSIS PROGRAM, AND SPECIMEN ANALYZER | SYSMEX CORPORATION (JP) | 2022-03-09 | — | — | EP | claimed |
| EP-3299997-B1 | VERIFICATION SYSTEM FOR A PHARMACY PACKAGING SYSTEM | RXSAFE LLC (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3955913-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | ENZYCHEM LIFESCIENCES (KR) | 2022-02-23 | — | — | EP | claimed |
| EP-3945863-A1 | FIELD BEAN PROTEIN COMPOSITION | ROQUETTE FRERES (FR) | 2022-02-09 | — | — | EP | claimed |
| EP-3945862-A1 | FIELD BEAN PROTEIN COMPOSITION | ROQUETTE FRERES (FR) | 2022-02-09 | — | — | EP | claimed |
| EP-3727662-B1 | SUBMICRONIC EMULSION | COATEX SAS (FR) | 2022-01-26 | — | — | EP | claimed |